Updated on 2024/08/26

Information

 

写真a

 
SHIOSE SATOMI
 
Organization
Faculty of Medical Sciences Department of Clinical Medicine Assistant Professor
School of Medicine Department of Medicine(Concurrent)
Title
Assistant Professor
Contact information
メールアドレス
Profile
clinical investigation for age related macular degeneration. clinical investigation for myopic macular neovascularization. clinical investigation for central serous chorioretinopathy.
External link

Research Interests・Research Keywords

  • Research theme:The effect of anti-VEGF drug for myopic macular neovascularization

    Keyword:myopic macular neovascularization

    Research period: 2022.9 - 2027.8

  • Research theme:The treatment effect for central serous chorioretinopathy

    Keyword:central serous chorioretinopathy

    Research period: 2022.6 - 2027.2

  • Research theme:age related macular degeneration

    Keyword:age-related macular degeneration myopic macular neovascularization

    Research period: 2020.3 - 2023.6

  • Research theme:age related macular degeneration

    Keyword:AMD

    Research period: 2018.4 - 2019.12

Papers

  • A Recurrent Case of Full-Thickness Macular Hole After Successful Closure With Primary Vitrectomy and Epiretinal Proliferation Embedding

    Notomi, S; Kubo, Y; Ishikawa, K; Shiose, S; Koh-Hei, S

    CUREUS JOURNAL OF MEDICAL SCIENCE   16 ( 8 )   2024.8   eISSN:2168-8184

  • Postoperative Proliferation Detection in Eyes Treated for Rhegmatogenous Retinal Detachment by WideField OCT Angiography

    Fukuda Y., Ishikawa K., Kiyohara K., Maehara Y., Ji R., Mori K., Kobayashi Y., Akiyama M., Nakama T., Notomi S., Shiose S., Takeda A., Sonoda K.H.

    Translational vision science & technology   13 ( 8 )   13   2024.8

     More details

    Language:English   Publisher:Translational vision science & technology  

    Purpose: Proliferative retinal changes may occur postsurgery for rhegmatogenous retinal detachment (RRD), possibly preceding recurrent detachment. This study aims to establish the groundwork for an imaging system capable of discerning changes in retinal vessel tortuosity after RRD repair, analyzing widefield optical coherence tomography angiography (WF-OCTA) images. Methods: Eighty-eight eyes of 86 patients with RRD who underwent surgical procedures and had repeated imaging with clear widefield optical coherence tomography (WF-OCT) and WF-OCTA on different postoperative days were enrolled in this retrospective study. We compared WF-OCTA images over time to identify alterations in retinal vessel tortuosity and observed regional changes in retinal morphology. Results: After image processing, changes in retinal vessel tortuosity were detected in 66 quadrants. These changes, attributed to retinal traction from proliferative membranes, were observed in 56 quadrants, among which retinal thickness remained unchanged in seven sectors (12.5%) according to the WF-OCT map. In nine quadrants, changes in retinal vessel tortuosity were attributed to changes in subretinal fluid, aligning with observable variations in retinal thickness. Conclusions: Observation of vessel tortuosity changes using WF-OCTA can help detect early postoperative proliferative changes in eyes with RRD. Translational Relevance: Because WF-OCTA can detect minute vessel tortuosity changes, it can offer a noninvasive alternative for the detection of early postoperative proliferative changes.

    DOI: 10.1167/tvst.13.8.13

    Scopus

    PubMed

  • Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population

    Fukuda, Y; Notomi, S; Shiose, S; Maehara, Y; Kiyohara, K; Fujiwara, K; Hashimoto, S; Kano, K; Ishikawa, K; Hisatomi, T; Sonoda, KH

    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY   2024.7   ISSN:0721-832X eISSN:1435-702X

     More details

    Language:English   Publisher:Graefe's Archive for Clinical and Experimental Ophthalmology  

    Purpose: This study aimed to compare the treatment outcomes of patients with neovascular age-related macular degeneration (nAMD) who initially received faricimab or aflibercept treatment using propensity score matching (PSM) to align patient backgrounds. Methods: Patients with treatment-naïve nAMD who received either faricimab or aflibercept for three consecutive monthly injections as the loading phase were enrolled in this study. In the 1:1 PSM, sex, age, best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and AMD subtypes in the pre-treatment state were selected as covariates. We examined the BCVA, CMT, CCT, and remaining fluid at 1-, 2-, and 3-month after the first injection. Results: After PSM, 43 eyes were included in the faricimab and aflibercept group each. Both groups showed significant improvements in BCVA, CMT, and CCT at 1-, 2-, and 3-month after the initial injection compared with baseline. Meanwhile, no significant differences were observed between the two groups at any time point regarding BCVA, CMT, and CCT. At 1-month, 18.6% of patients in the faricimab group and 41.9% in the aflibercept group demonstrated residual subretinal fluid or intraretinal fluid, with a significant difference between the groups (P = 0.03). Conclusion: The BCVA improved after three loading injections of both faricimab and aflibercept. Faricimab may provide a favorable early treatment response in reducing subretinal fluid in a Japanese cohort.

    DOI: 10.1007/s00417-024-06582-y

    Web of Science

    Scopus

    PubMed

  • The factors associated with retinal pigment epithelium tear development in the early phase after treatment initiation for age-related macular degeneration

    Shiose, S; Notomi, S; Hashimoto, S; Nagata, J; Fukuda, Y; Kano, K; Ishikawa, K; Sonoda, KH

    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY   2024.5   ISSN:0721-832X eISSN:1435-702X

     More details

    Language:English   Publisher:Graefe's Archive for Clinical and Experimental Ophthalmology  

    Purpose: This study aimed to evaluate the factors associated with retinal pigment epithelium (RPE) tear development in the early phase after anti-vascular endothelial growth factor (VEGF) drug initiation in eyes with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelial detachment (PED). Methods: Treatment-naive eyes with nAMD and PED for which anti-VEGF drug injections had been initiated and followed up for at least 3 months after the 1st anti-VEGF drug injection, were retrospectively investigated. Baseline characteristics of the PEDs, including type, height, and area, were evaluated using fundus photographs, fluorescein angiography, and optical coherence tomography images. The association between patient age, sex, medical history, PED characteristics, and the development of RPE tears within 3 months of starting anti-VEGF therapy was examined. Results: This study included 244 eyes (230 patients; mean age 75.0 years, 159 males and 71 females). RPE tears occurred in 13 eyes (5.3%) within 3 months of the start of anti-VEGF therapy. Multivariate analysis showed an association of the development of RPE tears with PED height (every 100 µm, odds ratio [OR]: 1.50, 95% confidence interval [CI]: 1.07–2.12, p = 0.019), PED area (every 10 mm2, OR: 3.02, CI: 1.22–7.46, p = 0.016), and the presence of fibrovascular PED (OR: 59.22, CI: 4.12–850.59, p = 0.002). Eyes with cleft (the hypo-reflective space beneath the fibrovascular PED) were more likely to develop an RPE tear (p = 0.01, χ-square test). Conclusions: Fibrovascular PED, large PED area, high PED height, and the cleft finding are independent risk factors for the development of RPE tears early after the administration of anti-VEGF drugs.

    DOI: 10.1007/s00417-024-06503-z

    Web of Science

    Scopus

    PubMed

  • SPATIAL PATTERN OF RETINAL PIGMENT EPITHELIUM TEAR DEVELOPMENT AND PROGRESSION AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Fukui T., Ishikawa K., Shiose S., Kano K., Mori K., Notomi S., Sonoda K.H.

    Retinal Cases and Brief Reports   18 ( 3 )   371 - 377   2024.5   ISSN:19351089

     More details

    Language:English   Publisher:Retinal Cases and Brief Reports  

    Purpose:The aim of this study was to demonstrate the spatial pattern of retinal pigment epithelium (RPE) tear development and progression after antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.Methods:We retrospectively reviewed six eyes with neovascular age-related macular degeneration that showed RPE tears after administration of intravitreal antivascular endothelial growth factor agents and were followed up for 12 months. The patterns of RPE tear development and progression were evaluated by analyzing positional relationships among the locations of the choroidal neovascularization membrane and pigment epithelial detachment (PED) area at baseline and the tear area using spectral-domain optical coherence tomography, color photography, fluorescein angiography, and fundus autofluorescence images.Results:Pretear OCT images revealed fibrovascular PED in all eyes, one of which showed complications of hemorrhagic PED after treatment. In five eyes, RPE tears developed at the PED edge located on the opposite side of the choroidal neovascularization membrane. In the eye showing hemorrhagic PED, the RPE tear developed along the wide area of the PED edge. The torn RPE monolayer contracted toward the side of the choroidal neovascularization membrane in all eyes, and RPE loss involved the fovea in five eyes that showed significantly worse visual acuity (VA) after 12 months in comparison with the baseline value before the tear (logMAR VA; 0.3 vs. 1.29; P < 0.02).Conclusion:The location of choroidal neovascularization membrane in PED determines the spatial pattern of RPE tear development and progression and helps to predict the visual outcome after RPE tears.

    DOI: 10.1097/ICB.0000000000001386

    Scopus

    PubMed

  • Wide-field choroidal thickness analysis after half-fluence photodynamic therapy combined with intravitreal aflibercept injection in pachychoroid neovasculopathy Reviewed International journal

    Fukuda Y, Notomi S, Shiose S, Maehara Y, Kiyohara K, Hashimoto S, Kano K, Ishikawa K, Hisatomi T, Sonoda KH

    J Clin Med 13(6):1608   2024.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Wide-Field Choroidal Thickness Analysis after Half-Fluence Photodynamic Therapy Combined with Intravitreal Aflibercept Injection in Pachychoroid Neovasculopathy

    Fukuda, Y; Notomi, S; Shiose, S; Maehara, Y; Kiyohara, K; Hashimoto, S; Kano, K; Ishikawa, K; Hisatomi, T; Sonoda, KH

    JOURNAL OF CLINICAL MEDICINE   13 ( 6 )   2024.3   ISSN:2077-0383 eISSN:2077-0383

     More details

    Language:English   Publisher:Journal of Clinical Medicine  

    Background: Pachychoroid neovasculopathy (PNV) is a pachychoroid-spectrum disease. As blood circulation throughout the choroid may be involved in PNV pathogenesis, analysis using ultra-wide-field (UWF) fundus imaging is crucial. We evaluated choroidal thickness after half-fluence photodynamic therapy (PDT) combined with intravitreal aflibercept injection for PNV using UWF swept-source optical coherence tomography. Methods: Seventeen eyes with PNV that underwent half-fluence PDT with an adjuvant single intravitreal aflibercept injection were analyzed. To compare choroidal thicknesses in the central and peripheral choroids, we set subfields <3, <9, and 9–18 mm from the fovea. The <9 and 9–18 mm subfields were divided into four quadrants. Results: Choroidal thickness in each subfield decreased significantly after half-fluence PDT (p < 0.001); this reduction was more pronounced in the central area. We also investigated the relationship between the dominant side of the deep choroidal veins that harbor choroidal vein efflux from the macula. When choroidal thickness in the supratemporal and infratemporal 9 mm subfields were evaluated, the ratio of choroidal thickness reduction was not significantly different between the dominant and non-dominant sides. The dominant side was not associated with the extent of choroidal thickness reduction in PNV. Conclusions: Half-fluence PDT caused thinning of the entire choroid, especially in the central area, in PNV.

    DOI: 10.3390/jcm13061608

    Web of Science

    Scopus

    PubMed

  • 連載 Clinical Challenge・46 網膜下索を伴う裂孔不明の胞状網膜剝離の症例

    納富 昭司, 塩瀬 聡美

    臨床眼科   78 ( 1 )   6 - 9   2024.1   ISSN:03705579 eISSN:18821308

     More details

    Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1410215061

    CiNii Research

  • 特集 新生血管型加齢黄斑変性に対する抗VEGF療法の現在 4 PDTの活用

    塩瀬 聡美

    眼科   66 ( 1 )   21 - 29   2024.1   ISSN:00164488

     More details

    Publisher:金原出版  

    DOI: 10.18888/ga.0000003475

    CiNii Research

  • Correction to: Persistence of vascular empty sleeves in choroidal neovascularization after anti-VEGF therapy in both animal models and humans (vol 261, pg 2189, 2023)

    Wada, I; Nakao, S; Fukuda, Y; Shiose, S; Takeda, A; Kannan, R; Sonoda, KH

    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY   261 ( 10 )   3047 - 3047   2023.10   ISSN:0721-832X eISSN:1435-702X

     More details

    Language:English   Publisher:Graefe's Archive for Clinical and Experimental Ophthalmology  

    In the published online version of this article, the title and the text contained mistakes. The authors would like to correct “VEGF therapy” to “anti-VEGF therapy”. The correct title is shown below: Persistence of vascular empty sleeves in choroidal neovascularization after anti-VEGF therapy in both animal models and humans. The correct Purpose is shown below: This study investigated whether the proposed mechanism is involved in CNV during anti-VEGF therapy. The correct Introduction is shown below: In this study, we investigated whether the proposed mechanism of vascular regrowth is involved in CNV during anti-VEGF therapy using a mouse model and long-term clinical observations in optical coherence tomography angiography (OCTA).

    DOI: 10.1007/s00417-023-06214-x

    Web of Science

    Scopus

    PubMed

  • Clinical Characteristics of Eyes with Neovascular Age-Related Macular Degeneration and Retinal Pigment Epithelium Tears

    Nagata, J; Shiose, S; Ishikawa, K; Fukui, T; Kano, K; Mori, K; Nakama, T; Notomi, S; Sonoda, KH; Yasukawa, T

    JOURNAL OF CLINICAL MEDICINE   12 ( 17 )   2023.9   ISSN:2077-0383 eISSN:2077-0383

     More details

    Language:English   Publisher:Journal of Clinical Medicine  

    Background: Although anti-vascular endothelial growth factor (anti-VEGF) therapy is the first choice of treatment for eyes with neovascular age-related macular degeneration (AMD), it sometimes results in retinal pigment epithelium (RPE) tears. This study presents the detailed clinical characteristics of RPE tears to help predict their occurrence before anti-VEGF therapy initiation. Methods: This study retrospectively analyzed neovascular age-related macular degeneration (nAMD) patients who visited the Kyushu University Hospital and started anti-VEGF therapy between April 2013 and June 2020. Using medical records, we collected the clinical data of patients with RPE tears, including age, sex, best-corrected visual acuity (BCVA), number of anti-VEGF drug injections and the type and size of pigment epithelial detachment (PED). Results: RPE tears occurred in 16 (1.50%) eyes of 16 patients in all 1068 nAMD eyes of 987 patients. The mean age of these patients with RPE tear was 81.7 ± 8.7 years. Fifteen eyes had typical AMD and one eye had polypoidal choroidal vasculopathy. The mean number of anti-VEGF drug injections before RPE tears was 5.0 ± 5.1. All patients experienced PED before the RPE tear (hemorrhagic, 4 eyes; serous vascular, 2 eyes; fibrovascular, 10 eyes). The average PED height and area were 615.7 ± 175.3 μm and 21.0 ± 7.2 mm2, respectively. The sub-RPE cleft was observed in 10 eyes. The logMAR BCVA immediately after the RPE tear (0.73 ± 0.40) at 6 months (0.86 ± 0.51) and 12 months (0.84 ± 0.43) after the RPE tear were significantly worse than that before the RPE tear (0.58 ± 0.31; p < 0.05). The BCVA of patients with RPE tears that spread to the fovea was poorer than that of patients without RPE tears. Conclusions: In patients with nAMD, RPE tears tended to occur in typical AMD eyes with high or large PEDs, and sub-RPE clefts. The visual prognosis depended on whether the RPE tear included the fovea.

    DOI: 10.3390/jcm12175496

    Web of Science

    Scopus

    PubMed

  • Differences in central and peripheral choroidal thickness among the subtypes of age-related macular degeneration in an Asian population Reviewed International journal

    Fukuda Y, Notomi S, Shiose S, Kano K, Hashimoto S, Fujiwara K, Akiyama M, Ishikawa K, Hisatomi T, Sonoda KH

    J Clin Med   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Clinical characteristics of neovascular age-related macular degeneration eyes with retinal pigment epithelium tears Reviewed International journal

    Nagata J, Shiose S, Ishikawa K, Fukui T, Kano K, Mori K, Nakama T, Notomi S, Sonoda KH

    J Clin Med.   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Persistence of vascular empty sleeves in choroidal neovascularization after VEGF therapy in both animal models and humans

    Wada, I; Nakao, S; Fukuda, Y; Shiose, S; Takeda, A; Kannan, R; Sonoda, KH

    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY   261 ( 8 )   2189 - 2197   2023.8   ISSN:0721-832X eISSN:1435-702X

     More details

    Language:English   Publisher:Graefe's Archive for Clinical and Experimental Ophthalmology  

    Purpose: Choroidal neovascularization (CNV) often recurs during anti-vascular endothelial growth factor (VEGF) therapy; however, little is known about the mechanism of vascular regrowth. Vascular regrowth along the empty sleeves of basement membranes was proposed as a mechanism for recurrence after the reversal of VEGF inhibition in tumors. This study investigated whether the proposed mechanism is involved in CNV during VEGF therapy. Methods: We made two observations using a mice model, as well as patients with CNV. Laser-induced CNV mice were used to examine the vascular empty sleeves of the basement membrane and CNV with the immunohistochemistry of type IV collagen and CD31, respectively. A retrospective cohort study included 17 eyes from 17 patients with CNV treated with anti-VEGF treatment. Vascular regrowth during anti-VEGF treatment was assessed using optical coherence tomography angiography (OCTA). Results: In the CNV mouse model, the CD31+ vascular endothelium area was decreased during anti-VEGF treatment compared with the IgG control (33516.7 ± 10864.7 vs. 10745.9 ± 5755.9 μm2, P < 0.05), whereas a significant difference was not observed in the area of type IV collagen+ vascular empty sleeve after the treatment compared with the control (29135.0 ± 7432.9 vs. 24592.0 ± 5935.3 μm2, P = 0.7). The proportions of CD31+ to type IV collagen+ areas were significantly decreased after the treatment (38.7 ± 7.4% vs. 17.1 ± 5.4%, P < 0.05). In the OCTA observations, the follow-up period in the retrospective cohort study was 58.2 ± 23.4 months. CNV regrowth was observed in 682 neovessels of the 17 eyes. In group 1, CNV regression and regrowth are in the same form (129 neovessels, 18.9%). In group 2, CNV regression and regrowth are in a different form (170 neovessels, 24.9%). In group 3, CNV regrowth is with a different form without the regression (383 neovessels, 56.2%).[Figure not available: see fulltext.] Conclusions: Parts of CNV regrowth may occur along the vascular empty sleeve, which remain after anti-VEGF treatment.

    DOI: 10.1007/s00417-023-06018-z

    Web of Science

    Scopus

    PubMed

  • Differences in Central and Peripheral Choroidal Thickness among the Subtypes of Age-Related Macular Degeneration in an Asian Population

    Fukuda, Y; Notomi, S; Shiose, S; Kano, K; Hashimoto, S; Fujiwara, K; Akiyama, M; Ishikawa, K; Hisatomi, T; Sonoda, KH

    JOURNAL OF CLINICAL MEDICINE   12 ( 16 )   2023.8   ISSN:2077-0383 eISSN:2077-0383

     More details

    Language:English   Publisher:Journal of Clinical Medicine  

    Age-related macular degeneration (AMD) causes visual impairment in individuals who are >50 years of age. However, no study has investigated AMD when using ultra-wide-field swept-source optical coherence tomography (UWF SS-OCT). We aimed to evaluate central and peripheral choroidal thicknesses using UWF SS-OCT, and to compare these across the AMD subtypes. We included 75 eyes of patients with typical AMD (tAMD), 56 with polypoidal choroidal vasculopathy (PCV), 29 with pachychoroid neovasculopathy (PNV), and 12 with retinal angiomatous proliferation (RAP). To compare choroidal thicknesses in the central and peripheral choroids, we established subfields of <3 mm, <9 mm, and 9–18 mm from the fovea. PNV patients were significantly younger than those with tAMD (p = 0.01). The choroidal thicknesses of PNV were significantly greater than that of tAMD in all subfields (p < 0.01), and choroidal thickness significantly correlated with age and axial length in all subfields (p < 0.05). Even after adjusting for age and axial length, the choroidal thickness in PNV was significantly greater than that in tAMD (p < 0.05). In addition, the ratio of the posterior <9 mm to a peripheral 9–18 mm choroidal thickness in PNV was significantly greater than that in tAMD (p < 0.01). A thickened choroid in PNV was more pronounced in the posterior choroid than in the periphery.

    DOI: 10.3390/jcm12165364

    Web of Science

    Scopus

    PubMed

  • Observation of choroidal vessels using ultra-wide-field optical coherence tomography in non-drusen type age-related macular degeneration

    Fukuda, Y; Notomi, S; Shiose, S; Kano, K; Hashimoto, S; Akiyama, M; Ishikawa, K; Sonoda, KH

    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE   64 ( 8 )   2023.6   ISSN:0146-0404 eISSN:1552-5783

     More details

  • 特集 第76回日本臨床眼科学会講演集[2] 原著 ポリープ状脈絡膜血管症に対する抗VEGF薬併用光線力学的療法後2年の治療成績

    山本 夏帆, 塩瀬 聡美, 納富 昭司, 福田 洋輔, 橋本 左和子, 中武 俊二, 狩野 久美子, 秋山 雅人, 石川 桂二郎, 園田 康平

    臨床眼科   77 ( 4 )   477 - 483   2023.4   ISSN:03705579 eISSN:18821308

     More details

    Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1410214765

    CiNii Research

  • ポリープ状脈絡膜血管症に対する抗VEGF薬併用光線力学的療法後2年の治療成績

    山本 夏帆, 塩瀬 聡美, 納富 昭司, 福田 洋輔, 橋本 左和子, 中武 俊二, 狩野 久美子, 秋山 雅人, 石川 桂二郎, 園田 康平

    臨床眼科   77 ( 4 )   477 - 483   2023.4   ISSN:0370-5579

     More details

    Language:Japanese   Publisher:(株)医学書院  

    <文献概要>目的:ポリープ状脈絡膜血管症(PCV)に対する抗血管内皮増殖因子(VEGF)薬併用光線力学的療法(PDT)後2年における治療成績の検討。対象と方法:対象は2017年8月~2019年8月に九州大学病院眼科で未治療PCVに初回からPDTと抗VEGF薬導入期3回投与(1クール)を施行し,2年以上経過観察できた20例20眼。眼底写真での新たな出血,光干渉断層計で確認された滲出性変化,および蛍光眼底造影でのポリープを認めたものを再発と定義した。治療前患者背景,治療前病巣径(GLD),治療前,1,2年後の視力,中心窩網膜厚(CRT),中心窩脈絡膜厚(CCT),dry fovea率,2年間の治療回数,再発率について,診療録をもとに後ろ向きに検討した。結果:治療前平均logMAR視力(0.23)は,1年後0.12,2年後0.14と改善し,治療前CRT(333.3±21.2μm),CCT(264.6±17.8μm)は,1年後(CRT 231.9±10.7μm,CCT 220.3±17.0μm),2年後(CRT 237.7±9.56μm,CCT 234.9±18.4μm)に減少していた(p<0.05)。1年後80%,2年後70%でdry foveaが得られていた。1年目の抗VEGF薬投与回数は導入期の3回を含めて平均4.65回±0.47回/年,2年目1.9回±0.60回/年であった。2年後の視力不良との関連因子を検討したところ,治療前視力不良,治療前GLDが大きいこと,と有意に関連があった。15例(75%)が再発し,そのうち40%が1年未満に再発していた。それらの早期再発症例の治療前平均CCT(234.9μm)は,1年以上後で再発した症例の平均CCT(314.3μm)に比べ有意に薄くなっていた。結論:PCVに対するPDT併用抗VEGF薬治療は2年後の視力,網膜形態を改善したが,症例により再発し,追加治療が必要となることが示唆された。治療前CCTが薄いと再発までの期間が短い傾向があった。

  • Persistence of vascular empty sleeves in choroidal neovascularization after VEGF therapy in both animal models and humans Reviewed International journal

    Wada I, Nakao S, Fukuda Y, Shiose S, Takeda A, Kannan R, Sonoda KH

    Graefes Arch Clin Exp Ophthalmol.   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Characteristics of retinal pigment epithelium elevations preceding exudative age-related macular degeneration in Japanese.

    Notomi, S; Shiose, S; Fukuda, Y; Mori, K; Hashimoto, S; Kano, K; Ishikawa, K; Sonoda, KH

    OPHTHALMIC RESEARCH   66 ( 1 )   108 - 115   2023   ISSN:0030-3747 eISSN:1423-0259

     More details

    Language:English   Publisher:Ophthalmic Research  

    Introduction: Drusen and pigmentary abnormality are found as the hallmark to predict progression of age-related macular degeneration (AMD). In Asian populations, exudative AMD often appears in the absence of drusen but is rather accompanied by pigmentary abnormality. Recently, shallow irregular retinal pigment epithelium (RPE) elevations (SIRE) have been shown as a sign of subclinical nonexudative macular neovascularization. In this study, we aimed to investigate the characteristics of optical coherence tomography (OCT) findings including SIRE before the appearance of exudative AMD. Methods: We retrospectively reviewed 32 cases of exudative AMD that occurred in the fellow eye within the 5-year-observation period. Color fundus photography, OCT, and fluorescein/indocyanine-green angiography at the beginning of observation and at the time when exudative AMD appeared were examined to diagnose SIRE and the subtype of exudative AMD. Results: Exudative AMD was found in 19 eyes with large drusen and 13 eyes without large drusen. Mean sub-foveal choroidal thickness without large drusen was significantly thicker than that with large drusen (336 ± 109 and 220 ± 96 μm, respectively; mean ± SD). Six eyes with pachychoroid neovasculopathy, 4 eyes with type 1 macular neovascularization, and 3 eyes with PCV had occurred in the fellow eye without large drusen. Among those, 6 eyes had been accompanied by SIRE with a greatest transverse linear dimension of 1 mm or more at the beginning of observation period. Besides, small RPE elevations with a longest diameter of less than 1 mm had been observed in other 5 eyes. Three cases of polypoidal choroidal vasculopathy had originated from small RPE elevations. Moreover, pachyvessels, choriocapillaris thinning, or choroidal hyperpermeability were observed with SIRE or small RPE elevations. Conclusions: There is a non-drusen type of exudative AMD that originates from small RPE elevations as well as SIRE.

    DOI: 10.1159/000526445

    Web of Science

    Scopus

    PubMed

  • Spatial pattern of retinal pigment epithelium tear development and progression after anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration International journal

    Fukui T, Ishikawa K, Shiose S, Kano K, Mori K, Notomi S, Sonoda KH

    Retin Cases Brief Rep.   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Characteristics of retinal pigment epithelium elevations preceding exudative age-related macular degeneration in Japanese. International journal

    Notomi S, Shiose S, Fukuda Y, Mori K, Hashimoto S, Kano K, Ishikawa K, Sonoda KH

    Ophthalmic Research   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • <i>TNFRSF10A</i> downregulation induces retinal pigment epithelium degeneration during the pathogenesis of age-related macular degeneration and central serous chorioretinopathy

    Mori, K; Ishikawa, K; Fukuda, Y; Ji, R; Wada, I; Kubo, Y; Akiyama, M; Notomi, S; Murakami, Y; Nakao, S; Arakawa, S; Shiose, S; Hisatomi, T; Yoshida, S; Kannan, R; Sonoda, KH

    HUMAN MOLECULAR GENETICS   31 ( 13 )   2194 - 2206   2022.7   ISSN:0964-6906 eISSN:1460-2083

     More details

    Language:English   Publisher:Human Molecular Genetics  

    Age-related macular degeneration (AMD) and central serous chorioretinopathy (CSC) are common diseases that can cause vision loss in older and younger populations. These diseases share pathophysiological conditions derived from retinal pigment epithelium (RPE) dysfunction. Tumor necrosis factor receptor superfamily 10A (TNFRSF10A)-LOC389641 with the same lead single-nucleotide polymorphism (SNP) (rs13278062) is the only overlapped susceptibility locus found in both AMD and CSC through genome-wide association studies. This lead SNP has been reported to alter the transcriptional activity of TNFRSF10A. This study aimed to elucidate the function of TNFRSF10A in RPE degeneration using human primary RPE cells and Tnfrsf10 knockout (Tnfrsf10-/-) mice. TNFRSF10A was found to be localized in human RPE. In vitro assays revealed that a T allele of rs13278062, the risk allele for AMD and CSC, downregulated TNFRSF10A transcription in RPE, leading to decreased cell viability and increased apoptosis through protein kinase C-α (PKCA) downregulation. Treatment with phorbol 12-myristate 13-Acetate, a PKC activator, rescued the cell viability. Morphological RPE abnormality was found in the retina of Tnfrsf10-/- mice. Our data suggest that downregulation of TNFRSF10A expression inactivates PKCA signaling and causes cellular vulnerability of the RPE, which may contribute to the pathogenesis of AMD and CSC.

    DOI: 10.1093/hmg/ddac020

    Web of Science

    Scopus

    PubMed

  • One-year efficacy of "rescue photodynamic therapy" for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovasculopathy refractory to anti-vascular endothelial growth factor therapy

    Wada, I; Shiose, S; Ishikawa, K; Kano, K; Notomi, S; Mori, K; Akiyama, M; Nakao, S; Sonoda, KH

    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY   260 ( 6 )   2029 - 2036   2022.6   ISSN:0721-832X eISSN:1435-702X

     More details

    Language:English   Publisher:Graefe's Archive for Clinical and Experimental Ophthalmology  

    Purpose: This study aimed to evaluate the one-year outcomes of photodynamic therapy (PDT) as a rescue treatment for age-related macular degeneration (AMD) refractory to anti-vascular endothelial growth factor (VEGF) therapy. Methods: Patients with AMD refractory to anti-VEGF therapy, treated with “rescue-PDT” were retrospectively investigated. The time of PDT was defined as the baseline value. Baseline characteristics including sex, age, best-corrected visual acuity (BCVA), central macular thickness (CMT), and foveal choroidal thickness (FCT) were examined. The changes in BCVA, CMT, and recurrence were also assessed at the 1-year follow-up. The logMAR VA change of 0.3 or more was defined as “improved” or “declined.” Results: Twenty-three consecutive eyes (typical AMD: 10 eyes, polypoidal choroidal vasculopathy: 10 eyes, and pachychoroid neovasculopathy: 3 eyes), which underwent “rescue-PDT,” were analyzed in this study. The BCVA was improved in three patients and maintained in 20 patients at 12 months after PDT (mean BCVA change: 0.11 ± 0.19). The CMT improved in 19 patients (82.6%), and the mean CMT changed from 318.5 ± 93.7 μm to 225.9 ± 51.6 μm (p < 0.01) 12 months after PDT. “Retreatment” of anti-VEGF drug injections was considered if the retinal fluid or retinal hemorrhage recurred after PDT. The baseline FCT of the “retreatment group (15 eyes)” was significantly lower than that of the “no retreatment group (8 eyes)” (206.3 ± 50.7 μm vs 293.9 ± 85.7 μm: p = 0.033). Conclusions: PDT could be an effective treatment option for anti-VEGF refractory AMD to maintain visual acuity and control retinal fluid for up to 12 months.

    DOI: 10.1007/s00417-022-05553-5

    Web of Science

    Scopus

    PubMed

  • Postoperative follow‐up of submacular hemorrhage displacement treated with vitrectomy and subretinal injection of tissue plasminogen activator Reviewed International journal

    2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • A case of bullous central serous chorioretinopathy treated with surgical removal of submacular fibrin and subsequent photodynamic therapy under silicone oil Reviewed International journal

    Notomi S, Shiose S, Kohno RI, Shimokawa S, Ishikawa K, Kano K, Mori K, Wada I, Fukuda Y, Nakatake S, Yamaguchi M, Sonoda KH

    Case Rep Ophthalmol.   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 硝子体切除術と組織プラスミノーゲンアクチベータの網膜下注入による黄斑下血腫移動の術後フォローアップ ガス充填眼における超広角視野眼底自発蛍光イメージング(Postoperative follow-up of submacular hemorrhage displacement treated with vitrectomy and subretinal injection of tissue plasminogen activator: ultrawide-field fundus autofluorescence imaging in gas-filled eyes)

    Fukuda Yosuke, Nakao Shintaro, Kohno Ri-ichiro, Ishikawa Keijiro, Shimokawa Sakurako, Shiose Satomi, Takeda Atsunobu, Morizane Yuki, Sonoda Koh-hei

    Japanese Journal of Ophthalmology   66 ( 3 )   264 - 270   2022.5   ISSN:0021-5155

     More details

    Language:English   Publisher:シュプリンガー・ジャパン(株)  

    網膜下血腫(SRH)移動目的に施行された硝子体切除術と網膜下組織プラスミノーゲンアクチベータ(t-PA)注入後のガス充填眼のフォローアップに用いられる超広角視野眼底自発蛍光イメージングの有用性について検討した。SRHを呈する24眼(男性12眼、女性12眼、平均76.8±9.8歳)に対して硝子体切除術と網膜下t-PA注入を行い、眼底自発蛍光像を評価してSRHの占拠率を算出した。主要評価項目は術後3日間におけるSRHの移動率、SRHの方向、術後の最良矯正視力(BCVA)とした。発症から手術施行までは平均11.5±6.6日で、13眼に対して白内障硝子体同時手術、11眼に硝子体切除を行い、術中のガス交換はSF6ガスが22眼、空気が2眼、平均観察期間は13.0±10.3ヵ月であった。網膜下黄斑血腫は24眼のうち20眼(83.3%)で下部外縁に移動しており、BCVAは術前の1.16±0.52から最終観察時に0.52±0.39と有意な改善が認められた。術後の黄斑下血腫領域は術前と比較して27.4%縮小しており、血腫占拠率は術翌日が63.5±39.7%、2日後が52.6±31.6%、3日後が61.2±40.3%となっていた。術後のガス充填眼の評価に超広角視野眼底自発蛍光イメージングは有用であることが示された。

  • Postoperative follow-up of submacular hemorrhage displacement treated with vitrectomy and subretinal injection of tissue plasminogen activator: ultrawide-field fundus autofluorescence imaging in gas-filled eyes

    Fukuda, Y; Nakao, S; Kohno, RI; Ishikawa, K; Shimokawa, S; Shiose, S; Takeda, A; Morizane, Y; Sonoda, KH

    JAPANESE JOURNAL OF OPHTHALMOLOGY   66 ( 3 )   264 - 270   2022.5   ISSN:0021-5155 eISSN:1613-2246

     More details

    Language:English   Publisher:Japanese Journal of Ophthalmology  

    Purpose: To investigate the utility of Optos ultrawide-field fundus autofluorescence (UWF-FAF) imaging for postoperative follow-up of gas-filled eyes after vitrectomy with subretinal tissue-plasminogen activator (t-PA) injection for subretinal hemorrhage (SRH) displacement. Study design: Retrospective consecutive case series. Methods: This study included 24 eyes with SRH. Vitrectomy with subretinal t-PA injection was performed, followed by postoperative prone positioning. FAF images acquired using Optos California were examined and the SRH occupancy in the macula was calculated. The main outcome measures were displacement rate and direction of SRH for 3 days postoperatively, and postoperative best-corrected visual acuity (BCVA). Results: The postoperative BCVA ranged from improvement (23 eyes; 95.8%) to no change (one eye; 4.2%). Analysis was done using postoperative Optos FAF images for 20 eyes (83.3%). Postoperative SRH occupancy was significantly reduced, by 27.4%, compared with the preoperative occupancy (P = 0.03). A statistically significant reduction was found between the preoperative and postoperative day (POD)1 (P = 0.04), but not between POD1 and POD2 (P = 0.7), or between POD2 and POD3 (P = 1.0). Conclusion: UWF-FAF imaging is useful for postoperative follow-up of gas-filled eyes after vitrectomy with subretinal t-PA injection for SRH displacement.

    DOI: 10.1007/s10384-022-00910-7

    Web of Science

    Scopus

    PubMed

  • TNFRSF10A downregulation induces retinal pigment epithelium degeneration during the pathogenesis of age-related macular degeneration and central serous chorioretinopathy Reviewed International journal

    Mori K, Ishikawa K, Fukuda Y, Rui ji, Wada I, Kubo Y, Akiyama M, Notomi Shoji, Murakami Y, Nakao S, Arakawa S, Shiose Satomi, Hisatomi T, Yoshida S, Ram Kannan, Sonoda KH

    Hum Mol Genet.   2022.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/hmg/ddac020.

  • One-year efficacy of "rescue photodynamic therapy" for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovasculopathy refractory to anti-vascular endothelial growth factor therapy Reviewed International journal

    Wada I, Shiose S, Ishikawa K, Kano K, Notomi S, Mori K, Akiyama M, Nakao S, Sonoda KH

    Graefes Arch Clin Exp Ophthalmol   260 ( 6 )   2029 - 2036   2022.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00417-022-05553-5.

  • Optical coherence tomography angiography of choroidal neovascularization in immune choroiditis following acute retinal necrosis

    Nakamura, S; Nakao, S; Shiose, S; Kohno, RI; Hasegawa, E; Sonoda, KH

    EUROPEAN JOURNAL OF OPHTHALMOLOGY   32 ( 1 )   NP114 - NP118   2022.1   ISSN:1120-6721 eISSN:1724-6016

     More details

    Language:English   Publisher:European Journal of Ophthalmology  

    Purpose: To report optical coherence tomography angiography (OCTA) findings in a case of immune choroiditis following contralateral acute retinal necrosis (ARN) with choroidal neovascularization (CNV) during anti-vascular endothelial growth factor (VEGF) therapy. Case report: A 64-year-old woman with immune choroiditis following contralateral ARN and secondary CNV presented with decreased visual acuity. Fundus examination revealed macular and peripheral yellowish lesions in the right eye. Inflammatory cells were observed in the anterior chamber and the vitreous. OCT revealed retinal exudative changes and subretinal lesions suggestive of CNV. OCTA detected an abnormal vascular net in the outer retina as well as choriocapillaris, corresponding to type 2 CNV, that reduced following intravitreous anti-VEGF therapy. Two weeks after treatment, OCTA showed re-dilated choroidal neovasculature at the outer retina despite no exudative recurrence in OCT. Six weeks after treatment, OCT detected exudative changes around the neovascular lesion. Conclusion: This case discusses the use of OCTA detection of CNV in a case of immune choroiditis following contralateral ARN. During anti-VEGF therapy for inflammatory CNV-related diseases, OCTA may be useful not only for CNV detection but also for the follow-up of CNV activity.

    DOI: 10.1177/1120672120977349

    Web of Science

    Scopus

    PubMed

  • A Case of Bullous Central Serous Chorioretinopathy Treated with Surgical Removal of Submacular Fibrin and Subsequent Photodynamic Therapy under Silicone Oil

    Notomi, S; Shiose, S; Kohno, RI; Shimokawa, S; Ishikawa, K; Kano, K; Mori, K; Wada, I; Fukuda, Y; Nakatake, S; Yamaguchi, M; Sonoda, KH

    CASE REPORTS IN OPHTHALMOLOGY   13 ( 2 )   385 - 392   2022   ISSN:1663-2699

     More details

    Language:English   Publisher:Case Reports in Ophthalmology  

    Bullous retinal detachment is a rare complication in the chronic phase of central serous chorioretinopathy (CSC). Only a small subset of eyes with chronic CSC develops into the bullous variant of CSC (bCSC). In patients with bCSC, the elevated concentration of fibrin in the subretinal space leads to persistent retinal detachment and eventually, severe vision loss. We experienced a case of unilateral bCSC with a massive accumulation of subretinal fibrin. Multiple leakage points and dilated choroidal veins were also observed. The patient underwent surgical removal of subretinal fibrin and silicone oil injection followed by photodynamic therapy (PDT). After this treatment, the retina was successfully reattached, and the affected eye was free from recurrent exudative changes for more than 18 months. Massive subretinal fibrin could be surgically removed to prevent the formation of subretinal fibrosis and retinal fold, and PDT under silicone oil can control the underlying exudative changes in bCSC.

    DOI: 10.1159/000524515

    Web of Science

    Scopus

    PubMed

  • TNFRSF10A downregulation induces retinal pigment epithelium degeneration during the pathogenesis of age-related macular degeneration and central serous chorioretinopathy

    塩瀬 聡美

    Hum Mol Genet   -   2022

     More details

  • Pachychoroid neovasculopathyに対する光線力学療法の短期治療成績 Reviewed

    福山文里, 塩瀬聡美, 石川桂二郎, 狩野久美子, 和田伊織, 森賢一郎, 海津嘉弘, 秋山雅人, 中間崇仁, 納富昭司, 園田康平

    臨床眼科   75   1227 - 1232   2021.9

     More details

    Language:Japanese  

  • Drusen and pigment abnormality predict the development of neovascular age-related macular degeneration in Japanese patients. Reviewed International journal

    Notomi S, Shiose S, Ishikawa K, Fukuda Y, Kano K, Mori K, Wada I, Kaizu Y, Matsumoto H, Akiyama M, Sonoda KH

    PLoS One   16 ( 7 )   2021.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0255213

  • Optical Coherence Tomography Angiography of Choroidal Neovascularization in Immune Choroiditis Following Acute Retinal Necrosis Reviewed International journal

    Nakamura S, Nakao S, Shiose S, Kohno RI, Hasegawa E, Sonoda KH

    Eur J Ophthalmol   2020.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • ポリープ状脈絡膜血管症に対する光線力学的療法併用抗血管内皮増殖因子治療後短期における治療成績と再発予測因子 Reviewed

    永吉美月, 塩瀬聡美, 和田伊織, 狩野久美子, 石川桂二郎, 秋山雅人, 森賢一郎, 納富昭司, 中尾新太郎, 久冨智朗, 園田康平

    臨床眼科   2020.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Vitrectomy with peripapillary internal limiting membrane peeling for macular retinoschisis associated with normal-tension glaucoma Reviewed International journal

    Ishikawa K, Fukui T, Nakao S, Shiose S, Sonoda KH

    Am J Ophthalmol Case Rep.   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients Reviewed

    Iori Wada, Yuji Oshima, Satomi Shiose, Kumiko Kano, Shintaro Nakao, Yoshihiro Kaizu, Shigeo Yoshida, Tatsuro Ishibashi, Koh hei Sonoda

    Graefe's Archive for Clinical and Experimental Ophthalmology   257 ( 7 )   1411 - 1418   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00417-019-04361-8

  • 近視性脈絡膜新生血管に対するラニビズマブ硝子体内注射の2年経過 Reviewed

    末廣久美子, 塩瀬聡美, 狩野久美子, 橋本左和子, 和田伊織, 大島裕司, 園田康平

    臨床眼科 73(7):871-877   2019.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Optical Coherence Tomography Angiography Detects Choriocapillaris Loss in Decalcification of Choroidal Osteoma Reviewed International journal

    Hoshiyama K, Nakao S, Shiose S, Yoshikawa H, Kano K, Kaizu Y, Murata T, Sonoda KH

    J Vitreoretin Dis.   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Two-year outcomes of intravitreal ranibizumab for myopic choroidal neovascularization Reviewed

    Kumiko Suehiro, Sacomi Shiose, Kumiko Kano, Sawako Hashimoto, Iori Wada, Yuji Oshima, Koh Hei Sonoda

    Japanese Journal of Clinical Ophthalmology   73 ( 7 )   871 - 877   2019.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 高血圧 動脈硬化 脂質異常と黄斑変性

    塩瀬 聡美

    日本の眼科   89 ( 10 )   1384 - 1389   2018.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 加齢黄斑変性に対する抗VEGF療法

    塩瀬 聡美

    あたらしい眼科   35   1165 - 1176   2018.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • A case of AIDS-related Kaposi sarcoma in the eyelid Reviewed

    Ken Ichi Takaki, Hiroshi Yoshikawa, Mika Tanabe, Satomi Shiose, Masayuki Murata, Minako Fujiwara, Koh Hei Sonoda

    Japanese Journal of Clinical Ophthalmology   72 ( 6 )   781 - 786   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • A case of orbital apex syndrome dead shortly after the onset Reviewed

    Masayoshi Seki, Ken Ichi Takaki, Hiroshi Yoshikawa, Mika Tanabe, Satomi Shiose, Noritaka Komune, Koh Hei Sonoda

    Folia Japonica de Ophthalmologica Clinica   10 ( 12 )   1004 - 1006   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Findings of chalazion by noncontact meibography Reviewed

    Ken Ichi Takaki, Hiroshi Yoshikawa, Naoyuki Morishige, Shuhei Kawahara, Ryoichi Arita, Satomi Shiose, Tatsuro Ishibashi

    Japanese Journal of Clinical Ophthalmology   70 ( 12 )   1785 - 1788   2016.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Primary amines protect against retinal degeneration in mouse models of retinopathies Reviewed

    Akiko Maeda, Marcin Golczak, Yu Chen, Kiichiro Okano, Hideo Kohno, Satomi Shiose, Kaede Ishikawa, William Harte, Grazyna Palczewska, Tadao Maeda, Krzysztof Palczewski

    Nature Chemical Biology   8 ( 2 )   170 - 178   2012.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/nchembio.759

  • Toll-like receptor 3 is required for development of retinopathy caused by impaired all-trans-retinal clearance in mice Reviewed

    Satomi Shiose, Yu Chen, Kiichiro Okano, Sanhita Roy, Hideo Kohno, Johnny Tang, Eric Pearlman, Tadao Maeda, Krzysztof Palczewski, Akiko Maeda

    Journal of Biological Chemistry   286 ( 17 )   15543 - 15555   2011.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1074/jbc.M111.228551

▼display all

Books

  • 新篇眼科プラクティス4 眼科薬物療法リファレンス

    塩瀬 聡美( Role: Joint author)

    2022.10 

     More details

    Language:Japanese   Book type:Scholarly book

Presentations

  • 実臨床におけるPCV治療 Invited

    塩瀬 聡美

    日本網膜硝子体学会  2019.12 

     More details

    Event date: 2019.12

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Country:Japan  

  • 生活習慣病と加齢黄斑変性

    塩瀬 聡美

    日本臨床眼科学会  2019.10 

     More details

    Event date: 2019.10

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:京都府   Country:Japan  

  • 加齢黄斑変性一問一答

    塩瀬 聡美

    日本臨床眼科学会  2019.10 

     More details

    Event date: 2019.10

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:京都府   Country:Japan  

  • 転移性脈絡膜腫瘍15例の検討

    塩瀬 聡美 吉川 洋  山名 佳奈子 高木 健一 田邉 美香 園田 康平       

    眼腫瘍学会  2018.11 

     More details

    Event date: 2018.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:金沢   Country:Japan  

  • バビースモの使用経験から視えてきた適する患者像 Invited

    塩瀬聡美

    網膜・黄斑疾患Conference in KOBE  2024.3 

     More details

    Event date: 2024.3

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:神戸市   Country:Japan  

  • 先生方のご質問にお答えします! AMD 診療 Q&A Invited

    塩瀬聡美

    第6回福岡眼科病診連携の会  2024.2 

     More details

    Event date: 2024.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡市   Country:Japan  

  • 亜急性に進行した原因不明の両眼性視神経症の1例

    弓削昂大, 秋山雅人, 石川桂二郎, 塩瀬聡美, 園田康平

    日本神経眼科学会  2023.12 

     More details

    Event date: 2023.12

    Language:Japanese  

    Venue:東京都   Country:Japan  

  • Vessel tortuosity changes post retinal detachment repair by wide-field OCT angiography International conference

    Fukuda Y, Ishikawa K, Notomi S, Kiyohara K, Maehara Y, Kubo Y, Okita A, Kobayashi Y, Shiose S, Takeda A, Sonoda KH

    The 3rd Asia Retinal Congress  2023.11 

     More details

    Event date: 2023.11

    Language:Japanese  

    Country:Japan  

  • 広角OCTを用いた網膜剥離術後の 網膜血管走行変化および網膜形態変化の検出

    福田洋輔, 石川桂二郎, 納富昭司, 清原鴻平, 前原裕亮, 久保夕樹, 沖田絢子, 小林義行, 塩瀬聡美, 武田篤信, 園田康平

    第62回日本網膜硝子体学会総会  2023.11 

     More details

    Event date: 2023.11

    Language:Japanese  

    Venue:横浜市   Country:Japan  

  • 患者さんのニーズから考える nAMD 治療の課題とは?

    塩瀬 聡美

    日本網膜硝子体学会  2023.4 

     More details

    Event date: 2023.11

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:横浜市   Country:Japan  

  • 中心性漿液性脈絡網膜症に対する光線力学的療法前後の脈絡膜厚変化

    前原裕亮, 塩瀬聡美, 納富昭司, 福田洋輔, 清原鴻平, 橋本左和子, 狩野久美子, 石川桂二郎, 園田康平

    第62回日本網膜硝子体学会総会  2023.11 

     More details

    Event date: 2023.11

    Language:Japanese  

    Venue:横浜市   Country:Japan  

  • 治療ナイーブ症例にバビースモを使ってみませんか?

    塩瀬 聡美

    中外eセミナーon ophthalmology  2023.10 

     More details

    Event date: 2023.10

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:北海道   Country:Japan  

  • 広角OCTを用いて観察した網膜剥離術後線維増殖の経時的変化

    清原鴻平, 石川桂二郎, 福田洋輔, 前原裕亮, 久保夕樹, 小林義行, 納富昭司, 塩瀬聡美, 武田篤信, 園田康平

    第77回日本臨床眼科学会  2023.10 

     More details

    Event date: 2023.10 - 2024.10

    Language:Japanese  

    Venue:東京都   Country:Japan  

  • 網膜毛細血管瘤を伴う難治性DMEに対するファリシマブ硝子体注射の治療効果検討

    小林義行, 石川桂二郎, 清原鴻平, 前原裕亮, 福田洋輔, 久保夕樹, 納富昭司, 塩瀬聡美, 武田篤信, 園田康平

    第60回 六大学合同眼科研究会  2023.9 

     More details

    Event date: 2023.9

    Language:Japanese  

    Venue:福岡県   Country:Japan  

  • バビースモ使用経験など

    塩瀬 聡美

    Woman’s macula Forum  2023.8 

     More details

    Event date: 2023.8

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Country:Japan  

  • 抗VEGF薬導入後早期の 網膜色素上皮裂孔発生に関連する因子の検討

    塩瀬聡美, 狩野久美子, 納富昭司, 永田純也, 福田洋輔, 橋本左和子, 石川桂二郎, 園田康平

    第39回眼循環学会  2023.7 

     More details

    Event date: 2023.7

    Language:Japanese  

    Venue:奈良県   Country:Japan  

  • 広角光干渉断層計を用いた増殖糖尿病網膜症に対する 硝子体手術後の網膜形態変化の観察

    福田洋輔, 石川桂二郎, 納富昭司, 沖田絢子, 小林義行, 塩瀬聡美, 武田篤信, 園田康平

    第29回日本糖尿病眼学会総会  2023.6 

     More details

    Event date: 2023.6 - 2023.7

    Language:Japanese  

    Venue:北海道   Country:Japan  

  • これからのAMD治療戦略

    塩瀬 聡美

    SENJU RETINA WEBセミナー  2023.6 

     More details

    Event date: 2023.6

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Country:Japan  

  • 球後神経炎に臨床所見が類似した視神経鞘髄膜腫の1例

    篠田昌宏, 林田陽, 中武俊二, 石川桂二郎, 秋山雅人, 塩瀬聡美, 園田康平

    第93回九州眼科学会  2023.5 

     More details

    Event date: 2023.5

    Language:Japanese  

    Venue:福岡県   Country:Japan  

  • AMD 診療マネジメントの現在

    塩瀬 聡美

    第93回九州眼科学会  2023.5 

     More details

    Event date: 2023.5

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:福岡県   Country:Japan  

  • 強度近視眼における近視性黄斑部新生血管に関連する因子の検討

    蜂谷 雪乃, 塩瀬聡美, 藤原康太, 納富昭司, 堀江宏一郎, 田崎渚沙, 長野水紀, 瀬戸寛子, 園田康平

    第5回日本近視学会総会  2023.5 

     More details

    Event date: 2023.5

    Language:Japanese  

    Venue:福岡県   Country:Japan  

  • nAMD治療のNext Choice -バビースモ

    塩瀬 聡美

    第5回日本近視学会総会  2023.5 

     More details

    Event date: 2023.5

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Country:Japan  

  • 加齢黄斑変性におけるリソソーム機能障害と網膜細胞死についての検討

    福田洋輔, 納富昭司, 徐梓茗, 呉冠男, 季鋭, 石川桂二郎, 塩瀬聡美, 村上祐介, 園田康平

    日本眼科学会総会  2023.11 

     More details

    Event date: 2023.4

    Language:Japanese  

    Venue:東京都   Country:Japan  

  • 感染性眼内炎Direct Strip PCRで検出されたキノロン耐性表皮ブドウ球菌による細菌性眼内炎の2例

    村上裕一, 伊東崇子, 八幡信代, 白根茉利子, 小林義行, 石川桂二郎, 塩瀬聡美, 長谷川英一, 武田篤信, 中野 聡子, 杉田 直, 鈴木 崇, 高瀬 博, 望月 學, 園田康平

    日本眼科学会総会  2023.4 

     More details

    Event date: 2023.4

    Language:Japanese  

    Venue:東京都   Country:Japan  

  • Observation of choroidal vessels using ultra-wide-field optical coherence tomography in non-drusen type age-related macular degeneration International conference

    Fukuda Y, Notomi S, Shiose S, Kano K, Hashimoto S, Akiyama M, Ishikawa K, Sonoda KH

    ARVO  2023.4 

     More details

    Event date: 2023.4

    Language:English  

    Country:United States  

  • Observation of choroidal vessels using ultra-wide-field optical coherence tomography in non-drusen type age-related macular degeneration International conference

    Fukuda Y, Notomi S, Shiose S, Kano K, Hashimoto S, Akiyama M, Ishikawa K, Sonoda KH

    FUJI RETINA  2023.3 

     More details

    Event date: 2023.3

    Language:English  

    Country:Japan  

  • 滲出性加齢黄斑変性に伴う網膜色素上皮裂孔の発生パターン

    福井卓磨, 石川桂二郎, 塩瀬聡美, 狩野久美子, 森賢一郎, 和田伊織, 海津嘉弘, 中間崇仁, 納富昭司, 園田康平

    九州大学眼科研究会  2023.2 

     More details

    Event date: 2023.2

    Language:Japanese  

    Venue:福岡市   Country:Japan  

  • nAMD治療のNext Choice -バビースモ Invited

    塩瀬聡美

    バビースモwebセミナー in 九州・沖縄  2023.2 

     More details

    Event date: 2023.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡県   Country:Japan  

  • ポリープ状脈絡膜血管症に伴う黄班下血腫 に対する硝子体手術の血腫移動率

    納富昭司, 福田洋輔, 中尾新太郎, 向野利一郎, 森賢一郎, 中武俊二, 狩野久美子, 石川桂二郎, 塩瀬聡美, 園田康平

    日本網膜硝子体学会総会  2022.12 

     More details

    Event date: 2022.12

    Language:Japanese  

    Country:Japan  

  • STTA and IVBr for wet AMD

    2022.12 

     More details

    Event date: 2022.12

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  • 抗VEGF療法におけるPDTの活用 Invited

    塩瀬聡美

    日本網膜硝子体学会総会  2022.12 

     More details

    Event date: 2022.12

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:大阪府   Country:Japan  

  • ポリープ状脈絡膜血管症に対する抗血管内皮増殖因子薬併用光線力学的療法後2年の治療成績

    山本夏帆, 塩瀬聡美, 納富昭司, 福田洋輔, 橋本左和子, 狩野久美子, 中武俊二, 石川桂二郎, 秋山雅人, 園田康平

    臨床眼科学会  2022.10 

     More details

    Event date: 2022.10

    Language:Japanese  

    Venue:東京都   Country:Japan  

  • 増殖糖尿病網膜症に対する硝子体手術後に網膜血管走行変化を認めた症例の臨床像

    秋山実美, 石川桂二郎, 福田洋輔, 小林義行, 納富昭司, 塩瀬聡美, 武田篤信, 園田康平

    日本糖尿病眼学会総会  2022.10 

     More details

    Event date: 2022.10

    Language:Japanese  

    Venue:京都府   Country:Japan  

  • 超広角OCT en face画像における 脈絡膜血管拡張とドルーゼンの関連

    福田洋輔, 納富昭司, 塩瀬聡美, 狩野久美子, 橋本左和子, 秋山雅人, 石川桂二郎, 園田康平

    日本眼循環学会  2022.7 

     More details

    Event date: 2022.7

    Language:Japanese  

    Country:Japan  

  • 加齢黄斑変性の病態を考えた治療戦略 Invited

    塩瀬聡美

    2022.6 

     More details

    Event date: 2022.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:沖縄県   Country:Japan  

  • 近視性脈絡膜新生血管に対するラニビズマブ硝子体内注射の5年経過

    森賢一郎, 塩瀬聡美, 納富昭司, 狩野久美子, 橋本左和子, 福田洋輔, 中武俊二, 秋山雅人, 石川桂二郎, 園田康平

    日本近視学会  2022.5 

     More details

    Event date: 2022.5

    Language:Japanese  

    Venue:大阪府   Country:Japan  

  • AMD診療アップデート Invited

    塩瀬 聡美

    第4回眼科診療Updateセミナー in MIYAZAKI  2021.2 

     More details

    Event date: 2022.5

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  • AMD治療アップデート Invited

    塩瀬 聡美

    網膜疾患update seminar in 福岡  2021.3 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • 典型AMDへの治療戦略 Invited

    塩瀬 聡美

    日本眼科学会総会  2021.4 

     More details

    Event date: 2022.5

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  • 劇症型中心性漿液性脈絡網膜症に対してシリコーンオイル下光線力学療法を施行した1例

    納富昭司, 塩瀬聡美, 向野利一郎, 石川桂二郎, 森賢一郎, 和田伊織, 福田洋輔, 中武俊二, 山口宗男, 園田康平

    日本眼循環学会  2021.9 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • ベオビュの現状の処方症例と今後の活用法

    塩瀬 聡美

    AMD expert clinical conference  2021.10 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • 加齢黄斑変性の病態を考慮した治療 Invited

    塩瀬 聡美

    バイエルレチナテラス  2021.10 

     More details

    Event date: 2022.5

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  • 2型脈絡膜新生血管を伴った 典型加齢黄斑変性に対する 抗VEGF薬治療後再発の検討

    福田洋輔, 塩瀬聡美, 石川桂二郎, 納富昭司, 狩野久美子, 秋山雅人, 和田伊織, 森賢一郎, 山口宗男, 園田康平

    日本臨床眼科学会  2021.10 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • 加齢黄斑変性に対する抗VEGF薬の治療効果に関する多施設共同研究(UNITE study)

    愛須奈央, 三宅正裕, 狩野久美子, 武内潤, 東惠子, 大音壮太郎, 塩瀬聡美, 片岡恵子, 小畑亮, 川崎良, 辻川明孝

    日本臨床眼科学会  2021.10 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • PDT適応を考える症例

    塩瀬聡美

    宮崎県黄斑疾患研究会1  2021.12 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • 肺小細胞癌に伴う傍腫瘍性視神経症に対してステロイド治療が奏効した1例

    浅原健一郎, 秋山雅人, 石津正崇, 石川桂二郎, 塩瀬聡美, 吉冨健志, 園田康平

    日本神経眼科学会総会  2021.12 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • 硝子体内注射の実際

    塩瀬聡美

    宮崎県黄斑疾患研究会2  2022.2 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • 九州大学病院における血管新生緑内障に対するチューブシャント手術の成績

    山口宗男, 森賢一郎, 中武俊二, 納富昭司, 石川桂二郎, 武田篤信, 塩瀬聡美, 園田康平

    九州大学眼科研究会  2022.2 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • 2型脈絡膜新生血管を伴った典型加齢黄斑変性に対する抗VEGF薬治療後再発の検討

    福田洋輔, 塩瀬聡美, 石川桂二郎, 納富昭司, 狩野久美子, 秋山雅人, 和田伊織, 森賢一郎, 山口宗男, 園田康平

    大分大学研究会  2022.3 

     More details

    Event date: 2022.5

    Language:Japanese  

    Country:Japan  

  • 近視性CNVと長くつきあうために Invited

    塩瀬聡美

    日本近視学会総会  2022.5 

     More details

    Event date: 2022.5

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:大阪府   Country:Japan  

  • 高齢で発症したレーベル遺伝性視神経症の1例

    孟彩英, 中武俊二, 石川桂二郎, 八坂裕太, 石津正崇, 秋山雅人, 塩瀬聡美, 園田康平

    九州眼科学会  2022.5 

     More details

    Event date: 2022.5

    Language:Japanese  

    Venue:沖縄県   Country:Japan  

  • 片眼性加齢黄斑変性の僚眼に生じた脈絡膜新生血管の病型に関する検討

    納富昭司, 塩瀬聡美, 福田洋輔, 森賢一郎, 中武俊二, 山口宗男, 橋本左和子, 狩野久美子, 石川桂二郎, 園田康平

    九州眼科学会  2022.5 

     More details

    Event date: 2022.5

    Language:Japanese  

    Venue:沖縄県   Country:Japan  

  • 九州大学病院における血管新生緑内障に対するチューブシャント手術の成績

    山口宗男, 森賢一郎, 中武俊二, 納富昭司, 石川桂二郎, 塩瀬聡美, 武田篤信, 園田康平

    九州眼科学会  2022.5 

     More details

    Event date: 2022.5

    Language:Japanese  

    Venue:沖縄県   Country:Japan  

  • 広角OCT angiographyによる増殖性網膜硝子体疾患の血管走行変化の検出

    福田洋輔, 石川桂二郎, 秋山雅人, 納富昭司, 森賢一郎, 山口宗男, 中武俊二, 塩瀬聡美, 武田篤信, 園田康平

    日本眼科学会総会  2022.4 

     More details

    Event date: 2022.4

    Language:Japanese  

    Venue:大阪府   Country:Japan  

  • 加齢黄斑変性に対する抗VEGF薬の治療効果に関する多施設共同研究(UNITE study)

    愛須奈央, 三宅正裕, 狩野久美子, 武内潤, 東惠子, 大音壮太郎, 塩瀬聡美, 片岡恵子, 小畑亮, 川崎良, 辻川明孝

    日本眼科学会総会  2022.4 

     More details

    Event date: 2022.4

    Language:Japanese  

    Venue:大阪府   Country:Japan  

  • Pachychoroid neovasculopathy における hyperreflective foci の治療前後の変化

    塩瀬聡美, 納富昭司, 石川桂二郎, 狩野久美子, 和田伊織, 橋本左和子, 森賢一郎, 福田洋輔, 秋山雅人, 中尾新太郎, 園田康平

    日本眼循環学会  2021.9 

     More details

    Event date: 2021.9

    Language:Japanese  

    Venue:京都府   Country:Japan  

  • 九州大学におけるBlorucizumab活用法 Invited

    塩瀬 聡美

    2020.12 

     More details

    Event date: 2020.12

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:福岡   Country:Japan  

  • 滲出型加齢黄斑変性に伴う網膜色素上皮裂孔の発生パターン

    福井卓磨, 石川桂二郎, 塩瀬聡美, 狩野久美子, 森賢一郎, 和田伊織, 海津嘉弘, 中間崇仁, 納富昭司, 園田康平

    網膜硝子体学会  2020.11 

     More details

    Event date: 2020.11

    Language:Japanese  

    Venue:福岡   Country:Japan  

  • Beovu News Flash ベオビュの今をしる Invited

    塩瀬 聡美

    2020.11 

     More details

    Event date: 2020.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡   Country:Japan  

  • 加齢黄斑変性一問一答 Invited

    塩瀬 聡美

    日本臨床眼科学会  2020.11 

     More details

    Event date: 2020.11

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:福岡   Country:Japan  

  • 加齢黄斑変性僚眼における前駆病変の滲出型への移行に関する検討

    納富昭司, 塩瀬聡美, 石川桂二郎, 狩野久美子, 森賢一郎, 和田伊織, 海津嘉弘, 秋山雅人, 園田康平

    日本網膜硝子体学会総会,  2020.11 

     More details

    Event date: 2020.11

    Language:Japanese  

    Venue:福岡   Country:Japan  

  • Pachychoroid neovasculopathyに対する光線力学療法の短期治療成績

    福山文里, 塩瀬聡美, 石川桂二郎, 狩野久美子, 和田伊織, 森賢一郎, 海津嘉弘, 秋山雅人, 中間崇仁, 納富昭司, 園田康平

    日本臨床眼科学会  2020.10 

     More details

    Event date: 2020.10 - 2022.10

    Language:Japanese  

    Venue:東京   Country:Japan  

  • AMDの最新治療 Invited

    塩瀬聡美

    2020.10 

     More details

    Event date: 2020.10

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:北九州市   Country:Japan  

  • ベオビュを臨床にどう生かす?

    塩瀬 聡美

    2020.10 

     More details

    Event date: 2020.10

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  • アイリーアの製剤特性とPCVの個別化治療 Invited

    塩瀬 聡美

    アイリーアの新提案 IN 九州  2020.10 

     More details

    Event date: 2020.10

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    Venue:福岡   Country:Japan  

  • AMD診療アップデート Invited

    塩瀬聡美

    筑豊ブロック眼科医会講演会  2020.9 

     More details

    Event date: 2020.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    Country:Japan  

  • ブロルシズマブの特性について Invited

    塩瀬聡美

    2020.8 

     More details

    Event date: 2020.8

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:福岡   Country:Japan  

  • AMD治療を再考する「当科でのBeovuの治療の位置づけ」 Invited

    塩瀬 聡美

    九州大学 信州大学 網膜合同カンファレンス  2020.8 

     More details

    Event date: 2020.8

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:福岡   Country:Japan  

  • AMDにおける抗VEGF療法後のCNV消退メカニズム

    和田伊織, 中尾新太郎, 海津嘉弘, 山口宗男, 森賢一郎, 石川桂二郎, 有馬充, 塩瀬聡美, 園田康平

    日本眼科学会総会  2020.4 

     More details

    Event date: 2020.4

    Language:Japanese  

    Venue:東京   Country:Japan  

  • 滲出型加齢黄斑変性に対するアフリベルセプト治療後の黄斑萎縮に関連する因子の検討

    福田洋輔, 塩瀬聡美, 和田伊織, 狩野久美子, 石川桂二郎, 秋山雅人, 森賢一郎, 海津嘉弘, 納富昭司, 中尾新太郎, 大島裕司, 園田康平

    日本網膜硝子体学会  2019.12 

     More details

    Event date: 2019.12

    Language:Japanese  

    Venue:長崎市   Country:Japan  

  • 正常眼圧緑内障を合併した黄斑分離症に対して硝子体手術が奏功した2例

    福井卓磨, 石川桂二郎, 塩瀬聡美, 向野利一郎, 園田康平

    日本網膜硝子体学会  2019.12 

     More details

    Event date: 2019.12

    Language:Japanese  

    Venue:長崎市   Country:Japan  

  • 当院におけるAMD診療 Invited

    塩瀬 聡美

    実戦黄斑疾患conference  2019.11 

     More details

    Event date: 2019.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:愛知県名古屋市   Country:Japan  

  • ポリープ状脈絡膜血管症への抗VEGF薬併用光線力学療法の再発率の検討

    永吉美月, 塩瀬聡美, 和田伊織, 狩野久美子, 石川桂二郎, 秋山雅人, 森賢一郎, 納富昭司, 中尾新太郎, 園田康平

    日本臨床眼科学会  2019.10 

     More details

    Event date: 2019.10

    Language:Japanese  

    Country:Japan  

  • 網膜下血腫移動術におけるOptos®自発蛍光眼底撮影の有用性

    福田洋輔, 向野利一郎, 中尾新太郎, 塩瀬聡美, 石川桂二郎, 海津嘉弘, 植田真史, 下川桜子, 園田康平

    日本臨床眼科学会  2019.10 

     More details

    Event date: 2019.10

    Language:Japanese  

    Venue:京都府   Country:Japan  

  • 正常眼圧緑内障に合併した黄斑分離症に対して硝子体手術が奏功した2例

    福井卓磨, 石川桂二郎, 塩瀬聡美, 向野利一郎, 園田康平

    六大学合同眼科研究会  2019.9 

     More details

    Event date: 2019.9

    Language:Japanese  

    Country:Japan  

  • Five-year outcomes following teat-and-extend therapy using aflibercept for neovascular age-related macular degeneration in Japanese patients. International conference

    Oshima Y, Shiose S, Kano K, Wada I, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Ishibashi T, Sonoda KH

    The 12th Joint meeting of Chinese-Japanese-Korean Ophthalmologists  2019.9 

     More details

    Event date: 2019.9

    Language:English  

    Country:China  

  • 最近の知見に基づいたAMD治療アップデート

    塩瀬 聡美

    第19回九州黄斑疾患研究会  2019.8 

     More details

    Event date: 2019.8

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡市   Country:Japan  

  • 加齢黄斑変性に対するアフリベルセプトtreat and extend法の5年成績

    大島裕司, 塩瀬聡美, 狩野久美子, 石川桂二郎, 中尾新太郎, 和田伊織, 海津嘉弘, 長谷川英一, 園田康平

    日本眼循環学会  2019.7 

     More details

    Event date: 2019.7

    Language:Japanese  

    Venue:北海道札幌市   Country:Japan  

  • 症例から考えるAMD診療

    塩瀬 聡美

    AMDエリア講演会  2019.7 

     More details

    Event date: 2019.7

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡市   Country:Japan  

  • 滲出型加齢黄斑変性における”rescue PDT” 半年間の治療成績について

    和田伊織, 塩瀬聡美, 狩野久美子, 海津嘉弘, 石川桂二郎, 中尾新太郎, 園田康平

    日本眼循環学会  2019.7 

     More details

    Event date: 2019.7

    Language:Japanese  

    Country:Japan  

  • 治療に難渋する症例の特徴~萎縮を中心に~ Invited

    塩瀬 聡美

    2019.6 

     More details

    Event date: 2019.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡市   Country:Japan  

  • An association between RPE disruption and fibrotic scar formation after aflibercept therapy for neovascular age-related macular degeneration International conference

    Ishikawa K, Shiose S, Akiyama M, Kano K, Kaizu Y, Wada I, Nakao S, Oshima Y, Sonoda KH

    ARVO  2019.4 

     More details

    Event date: 2019.4 - 2019.5

    Language:English  

    Country:Canada  

  • 深層学習によるIgG4関連疾患とMALTリンパ腫の病理画像の鑑別

    秋山雅人, 左野裕介, 関瑛子, 塩瀬聡美, 吉川洋, 田邉美香, 園田康平

    日本眼科学会総会  2019.4 

     More details

    Event date: 2019.4 - 2019.3

    Language:Japanese  

    Venue:東京   Country:Japan  

  • 眼瞼脂腺癌3例のエクソーム解析

    左野裕介, 秋山雅人, 藤井裕也, 関瑛子, 髙木健一, 山名佳奈子, 塩瀬聡美, 吉川洋, 田邉美香, 園田康平

    九州大学眼科研究会  2019.2 

     More details

    Event date: 2019.2

    Language:Japanese  

    Country:Japan  

  • 孤立性脈絡膜血管腫に対するベルテポルフィンによる光線力学療法の効果

    関瑛子, 田邉美香, 秋山雅人, 藤井裕也, 左野裕介, 塩瀬聡美, 吉川洋, 園田康平

    九州大学眼科研究会  2019.2 

     More details

    Event date: 2019.2

    Language:Japanese  

    Country:Japan  

  • 血腫移動術におけるOptos自発蛍光眼底撮影の有用性

    福田洋輔, 向野利一郎, 中尾新太郎, 塩瀬聡美, 植田真史, 石川桂二郎, 園田康平

    九州大学眼科研究会  2019.2 

     More details

    Event date: 2019.2

    Language:Japanese  

    Venue:福岡   Country:Japan  

  • 近視性脈絡膜新生血管に対するラニビズマブ硝子体内注射の2年経過

    末廣久美子, 塩瀬聡美, 狩野久美子, 橋本左和子, 和田伊織, 大島裕司, 園田康平

    九州大学眼科研究会  2019.2 

     More details

    Event date: 2019.2

    Language:Japanese  

    Venue:福岡   Country:Japan  

  • The new development quantification system for the evaluation of disease activity in exudative age-related macular degeneration by using en face hyperreflective foci International conference

    Wada I, Nakao S, Kaizu Y, Yamaguchi M, Arima M, Ishikawa K, Kano K, Shiose S, Oshima Y, Ishibashi T, Sonoda KH

    6TH INTERNATIONAL CONGRESS ON OCT ANGIOGRAPHY AND ADVANCES IN OCT  2018.12 

     More details

    Event date: 2018.12

    Language:English  

    Country:Italy  

  • OCT angiography detects re-dilation of choroidal neovasculatures before exudative recurrence in multifocal choroiditis with panuveitis: a case report International conference

    Nakamura S, Nakao S, Shiose S, Kohno RI, Hasegawa E, Kano K, Kaizu Y, Seki E, Sonoda KH

    The 11th Joint Meeting of Japan-China-Korea Ophthalmologists  2018.12 

     More details

    Event date: 2018.12

    Language:English  

    Country:Japan  

  • Clinical features of sebaceous carcinoma of the eyelid in 121 Japanese patients International conference

    Sano Y, Akiyama M, Takaki K, Fujii Y, Seki E, Shiose S, Yoshikawa H, Tanabe M, Sonoda KH

    The 11th Joint Meeting of Japan-China-Korea Ophthalmologists  2018.12 

     More details

    Event date: 2018.12

    Language:English  

    Country:Japan  

  • The evaluation of disease activity in exudative age-related macular degeneration using en face hyperreflective foci International conference

    Wada I, Nakao S, Shiose S, Kaizu Y, Yamaguchi M, Arima M, Ishikawa K, Kano K, Oshima Y, Ishibashi T, Sonoda KH

    The 11th Join Meeting of Japan-China-Korea Ophthalmologists  2018.12 

     More details

    Event date: 2018.12

    Language:Japanese  

    Country:Japan  

  • PDTを用いたPCVの治療戦略 Invited

    塩瀬 聡美

    PDT conference  2018.11 

     More details

    Event date: 2018.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:福岡市   Country:Japan  

  • Three-year Outcomes Following Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration in Japanese Patients International conference

    Hashiguchi N, Oshima Y, Shiose S, Kano K, Ishikawa K, Wada I, Funatsu H, Ishibashi T, Sonoda KH

    The 11th Joint Meeting of Japan-China-Korea Ophthalmologists  2018.12 

     More details

    Event date: 2018.11

    Language:English  

    Country:Japan  

  • 加齢黄斑変性に対するアフリベルセプト投与後に網膜下線維化をきたす症例の特徴

    石川桂二郎, 塩瀬聡美, 秋山雅人, 狩野久美子, 森賢一郎, 海津嘉弘, 和田伊織, 長谷川英一, 中尾新太郎, 大島裕司, 園田康平

    日本網膜硝子体学会総会  2018.11 

     More details

    Event date: 2018.11

    Language:English  

    Venue:京都府   Country:Japan  

  • 孤立性脈絡膜血管腫に対するベルテポルフィンによる光線力学療法の効果

    関瑛子, 田邉美香, 秋山雅人, 藤井裕也, 左野裕介, 塩瀬聡美, 吉川洋, 園田康平

    眼腫瘍学会  2018.11 

     More details

    Event date: 2018.11

    Language:Japanese  

    Country:Japan  

  • ポリープ上脈絡膜血管症の性状によるアフリベルセプト治療への反応性検討

    塩瀬聡美、狩野久美子、橋本佐和子、秋山雅人 、末廣久美子、和田伊織、大島裕司、園田康平

    臨床眼科学会  2018.10 

     More details

    Event date: 2018.10

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  • 近視性脈絡膜新生血管に対するラニビズマブ硝子体内注射の2年経過

    末廣久美子, 塩瀬聡美, 狩野久美子, 橋本左和子, 和田伊織, 大島裕司, 園田康平

    日本臨床眼科学会  2018.10 

     More details

    Event date: 2018.10

    Language:Japanese  

    Venue:東京   Country:Japan  

  • 多巣性脈絡膜炎に伴う脈絡膜新生血管の診断と治療評価にOCT angiographyが 有用だった1例

    中村駿, 中尾新太郎, 塩瀬聡美, 向野利一郎, 長谷川英一, 狩野久美子, 海津嘉弘, 関瑛子, 園田康平

    六大学眼科合同研究会  2018.9 

     More details

    Event date: 2018.9

    Language:Japanese  

    Venue:福岡市   Country:Japan  

  • AMDの活動性マーカーとしての En Face OCTによるhyperreflective foci

    和田伊織, 中尾新太郎, 大島裕司, 海津嘉弘, 山口宗男, 有馬充, 石川桂二郎, 狩野久美子, 塩瀬聡美, 石橋達朗, 園田康平

    日本眼循環学会  2018.7 

     More details

    Event date: 2018.7

    Language:Japanese  

    Venue:松本市   Country:Japan  

  • 黄斑疾患の診断と治療 Invited

    塩瀬 聡美

    豊後レチナクラブ  2018.5 

     More details

    Event date: 2018.5

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大分   Country:Japan  

  • 多量の黄斑下血腫に対するtPA注入併用硝子体手術の治療成績

    植田真史, 長谷川英一, 向野利一郎, 塩瀬聡美, 大島裕司, 園田康平

    九州眼科学会  2018.5 

     More details

    Event date: 2018.5

    Language:Japanese  

    Venue:長崎   Country:Japan  

  • AMDにおけるアフリベルセプト固定投与からファリシマブ固定投与への切り替え効果

    前原 裕亮, 納富 昭司, 塩瀬 聡美, 福田 洋輔, 清原 鴻平, 橋本 左和子, 狩野 久美子, 石川 桂二郎, 園田 康平

    日本眼科学会雑誌  2024.3  (公財)日本眼科学会

     More details

    Language:Japanese  

  • ブロルシズマブの副作用を予防するためのSub-Tenonステロイド 多施設研究(Sub-Tenon steroid to prevent side effects of brolucizumab: amulticenter study)

    Ando Ryo, Kato Aki, Kimoto Kenichi, Hikichi Taiichi, Watanabe Goro, Sato Taku, Matsuda Hideho, Shiose Satomi, Matsubara Hisashi, Saito Masaaki, Yasukawa Tsutomu, Ishida Susumu

    眼科臨床紀要  2023.9  眼科臨床紀要会

     More details

    Language:English  

  • ポリープ状脈絡膜血管症に伴う黄斑下血腫に対する硝子体手術の血腫移動率

    納富 昭司, 福田 洋輔, 中尾 新太郎, 向野 利一郎, 森 賢一郎, 中武 俊二, 狩野 久美子, 石川 桂二郎, 塩瀬 聡美, 園田 康平

    眼科臨床紀要  2023.10  眼科臨床紀要会

     More details

    Language:Japanese  

  • 亜急性に進行した原因不明の両眼性視神経症の1例

    弓削 昂大, 秋山 雅人, 石川 桂二郎, 塩瀬 聡美, 園田 康平

    神経眼科  2023.11  日本神経眼科学会

     More details

    Language:Japanese  

  • 加齢黄斑変性におけるリソソーム機能障害と網膜細胞死についての検討

    福田 洋輔, 納富 昭司, 徐 梓茗, 呉 冠男, 季 鋭, 石川 桂二郎, 塩瀬 聡美, 村上 祐介, 園田 康平

    日本眼科学会雑誌  2023.3  (公財)日本眼科学会

     More details

    Language:Japanese  

  • 加齢黄斑変性に対するアフリベルセプトとラニビズマブの大規模多施設比較研究 UNITE study

    三宅 正裕, 愛須 奈央, 塩瀬 聡美, 片岡 恵子, 小畑 亮, 川崎 良, 辻川 明孝

    眼科  2023.9  金原出版(株)

     More details

    Language:Japanese  

  • 加齢黄斑変性に対する抗VEGF薬の治療効果に関する多施設共同研究(UNITE study)

    愛須 奈央, 三宅 正裕, 狩野 久美子, 武内 潤, 東 惠子, 大音 壮太郎, 塩瀬 聡美, 片岡 恵子, 小畑 亮, 川崎 良, 辻川 明孝

    日本眼科学会雑誌  2022.3  (公財)日本眼科学会

     More details

    Language:Japanese  

  • 増殖糖尿病網膜症に対する硝子体手術後に網膜血管走行変化を認めた症例の臨床像

    秋山 実美, 石川 桂二郎, 福田 洋輔, 小林 義行, 納富 昭司, 塩瀬 聡美, 武田 篤信, 園田 康平

    糖尿病合併症  2022.9  (一社)日本糖尿病合併症学会

     More details

    Language:Japanese  

  • 広角OCT angiographyによる増殖性網膜硝子体疾患の血管走行変化の検出

    福田 洋輔, 石川 桂二郎, 秋山 雅人, 納富 昭司, 森 賢一郎, 山口 宗男, 中武 俊二, 塩瀬 聡美, 武田 篤信, 園田 康平

    日本眼科学会雑誌  2022.3  (公財)日本眼科学会

     More details

    Language:Japanese  

  • 広角OCTを用いた加齢黄斑変性の病型間における脈絡膜厚の比較

    福田 洋輔, 納富 昭司, 塩瀬 聡美, 清原 鴻平, 前原 裕亮, 藤原 康太, 橋本 左和子, 狩野 久美子, 秋山 雅人, 石川 桂二郎, 園田 康平

    日本眼科学会雑誌  2024.3  (公財)日本眼科学会

     More details

    Language:Japanese  

  • 感染性眼内炎Direct Strip PCRで検出されたキノロン耐性ブドウ球菌による眼内炎の2例

    村上 裕一, 伊東 崇子, 八幡 信代, 白根 茉利子, 小林 義行, 石川 桂二郎, 塩瀬 聡美, 長谷川 英一, 武田 篤信, 中野 聡子, 杉田 直, 鈴木 崇, 高瀬 博, 望月 學, 園田 康平

    日本眼科学会雑誌  2023.3  (公財)日本眼科学会

     More details

    Language:Japanese  

  • 抗VEGF療法の実情と新展開 加齢黄斑変性,近視性脈絡膜新生血管編 抗VEGF療法におけるPDTの活用

    塩瀬 聡美

    眼科臨床紀要  2023.9  眼科臨床紀要会

     More details

    Language:Japanese  

▼display all

MISC

  • 新生血管型加齢黄斑変性に対する抗VEGF療法の現在:PDTの活用

    塩瀬聡美

    眼科 66巻1号:21-29   2024.1

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • 【新生血管型加齢黄斑変性に対する抗VEGF療法の現在】PDTの活用

    塩瀬 聡美

    眼科   66 ( 1 )   21 - 29   2024.1   ISSN:0016-4488

     More details

    Language:Japanese   Publisher:金原出版(株)  

  • Clinical Challenge 網膜下索を伴う裂孔不明の胞状網膜剥離の症例

    納富 昭司, 塩瀬 聡美

    臨床眼科   78 ( 1 )   6 - 9   2024.1   ISSN:0370-5579

     More details

    Language:Japanese   Publisher:(株)医学書院  

  • 近視性黄斑症管理の最前線

    塩瀬聡美

    あたらしい眼科   2023.2

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • 【近視外来の最前線】成人の近視と長期予後 近視性黄斑症管理の最前線

    塩瀬 聡美

    あたらしい眼科   40 ( 2 )   183 - 191   2023.2   ISSN:0910-1810

     More details

    Language:Japanese   Publisher:(株)メディカル葵出版  

  • 安全・迅速な抗VEGF薬硝子体内注射のコツと注意点

    塩瀬聡美

    あたらしい眼科   2022.4

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • 抗VEGF治療セミナー 安全・迅速な抗VEGF薬硝子体内注射のコツと注意点

    塩瀬 聡美, 安川 力, 高橋 寛二

    あたらしい眼科   39 ( 4 )   479 - 480   2022.4   ISSN:0910-1810

     More details

    Language:Japanese   Publisher:(株)メディカル葵出版  

    抗VEGF薬が最初に認可されてから13年が経過したが、その適応疾患の拡大とともに、各診療施設での抗VEGF薬硝子体内投与の頻度は年々増加しており、今後も増加していくことが予想される。そのような状況下で、安全かつ迅速に投与を行っていくことは、今後の眼科診療において大変重要であると考えられる。(著者抄録)

  • 抗VEGF治療:加齢黄斑変性の長期マネジメント

    中間崇仁, 塩瀬聡美

    あたらしい眼科   2021.3

     More details

    Language:Japanese  

▼display all

Professional Memberships

  • 日本網膜硝子体学会

  • 日本眼科学会

  • 日本眼循環学会

Research Projects

  • 加齢黄斑変性(AMD)患者のアンメットニーズに応える新たな抗線維化治療 (Agrinを標的にした抗線維化治療の可能性)

    2019.4 - 2021.3

    九州大学大学院医学研究院眼科学分野 

      More details

    Authorship:Principal investigator 

  • 加齢黄斑変性(AMD)患者のアンメットニーズに応える新たな抗線維化治療

    Grant number:19K09931  2019 - 2021

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    塩瀬 聡美, 石川 桂二郎, 園田 康平, 秋山 雅人, 久冨 智朗, 有馬 充

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    加齢黄斑変性(AMD)の治療は、脈絡膜新生血管(CNV)に対する治療が中心で、治療後生じる網膜下線維化に有効な治療はない。最終的に網膜下線維化による視機能障害がおこるため、この線維化への対策が不可欠である。線維化に関する様々な蛋白をターゲットとした治療が試みられているが、未だ実用化されていない。我々は、新たなターゲットとしてagrinという蛋白に着目し、網膜下線維巣に有意にagrinが発現していることを、マウスレーザー誘導性CNVモデルにより証明した。網膜下線維化のメカニズムを明らかにし、agrin を標的とした新たな治療を確立することは、AMD 患者のアンメットニーズに応える治療戦略となる。

    CiNii Research

  • 加齢黄斑変性患者の長期治療成績を検討する後ろ向き研究

    2018.6 - 2023.6

    九州大学大学院医学研究院眼科学分野 

      More details

    Authorship:Coinvestigator(s) 

    難治疾患である滲出型加齢黄斑変性に対して、抗VEGF療法やPDT単独療法、PDT併用療法の治療効果 長期治療成績を後ろ向きに検討する。

Class subject

  • 角結膜 白内障 網膜疾患

    2023.10 - 2024.3   Second semester

  • 保健学科講義 角膜 結膜 白内障 網膜

    2022.10 - 2023.3   Second semester

  • 保健学科講義 角膜 結膜 白内障 網膜

    2021.10 - 2022.3   Second semester

  • 保健学科講義 眼科 角膜 結膜 腫瘍 網膜

    2020.10 - 2021.3   Second semester

Visiting, concurrent, or part-time lecturers at other universities, institutions, etc.

  • 2023  看護学科講義  Classification:Part-time lecturer  Domestic/International Classification:Japan 

    Semester, Day Time or Duration:2023/12/08

  • 2023  宮崎大学非常勤  Classification:Part-time lecturer  Domestic/International Classification:Japan 

  • 2023  福岡国際医療福祉大学 視能訓練科  Classification:Part-time lecturer  Domestic/International Classification:Japan 

    Semester, Day Time or Duration:2023年7月

  • 2022  宮崎大学非常勤  Classification:Part-time lecturer 

  • 2022  看護学科講義  Classification:Part-time lecturer  Domestic/International Classification:Japan 

  • 2022  福岡国際医療福祉大学 視能訓練科  Classification:Part-time lecturer  Domestic/International Classification:Japan 

  • 2021  福岡国際医療福祉大学 視能訓練科  Classification:Part-time lecturer  Domestic/International Classification:Japan 

  • 2021  看護学科講義  Classification:Part-time lecturer  Domestic/International Classification:Japan 

▼display all

Other educational activity and Special note

  • 2023  Special Affairs 

  • 2023  Special Affairs 

  • 2023  Special Affairs 

  • 2022  Special Affairs 

  • 2022  Special Affairs 

  • 2022  Special Affairs 

▼display all

Social Activities

  • アイフレイル相談医

    2023

     More details

    アイフレイル相談医

  • アイフレイル相談医

    2022

     More details

    アイフレイル相談医

Media Coverage

  • よかラボ これからも一緒に過ごす「目」の健康! TV or radio program

    2024.4

     More details

    よかラボ これからも一緒に過ごす「目」の健康!

  • 加齢黄斑変性について TV or radio program

    とっても健康ランド  2019.9

     More details

    加齢黄斑変性について

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Surgical Clinical Medicine / Ophthalmology

Clinician qualification

  • Specialist

    Japanese Ophthalmological Society(JOS)

  • Certifying physician

    日本網膜硝子体学会

Year of medical license acquisition

  • 1995